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Reduced urinary NOx, but not nitroso 
species, excretion is associated with 
increased mortality and graft failure 
in renal transplant recipients
AS Frenay
















Graft failure and mortality are prevalent in renal transplant recipients (RTR). A reduced 
production of nitric oxide (NO) may contribute to these adverse events. We therefore 
investigated potential associations of urinary excretion of the NO metabolites nitrite 
and nitrate (NOx) and formation of nitroso species (RXNO), with cardiovascular 
parameters and patient/graft survival in RTR. NOx and RXNO concentrations were 
determined in 24h urine samples of 702 RTR (age 53 ± 13 yrs, 57% male, median time 
since transplantation 5.4 [1.9-12.0] yrs) and 107 healthy controls using Griess assay, 
HPLC and gas-phase chemiluminescence. Information on dietary habits, health and 
drug use was obtained, and standard hemodynamics and renal function measured. 
Associations of NOx with all-cause mortality and graft failure were assessed using Cox 
regression analyses. Urinary NOx levels were lower in RTR than controls (679 [389-
1053] vs. 1204 [879-2014] µmol/24h, P < 0.001), while vegetable intake was similar. In 
multivariate regression analysis, smoking, BSA, serum triglycerides, urinary uric acid 
and the use of calcineurin inhibitors and sirolimus were the strongest associates of NOx 
(model R2=0.27). After adjustment for these factors, NOx was inversely associated with 
systolic blood pressure, diastolic blood pressure, hsCRP, NT-pro-BNP and HbA1c. During 
a follow-up of 3.1 [2.7 – 3.9] yrs, 83 patients died and 45 developed graft failure. NOx 
was inversely associated with all-cause mortality (HR 0.59 [95% CI 0.59 – 0.84], P < 0.001) 
and graft failure (HR 0.59 [0.48 – 0.73], P = 0.001). RXNO excretion was associated 
with nitrite (R2=0.052, st. β: 0.137, P = 0.001), but not nitrate excretion. Urinary RXNO 
was significantly associated with SBP, DBP and albuminuria, but did neither predict 
graft failure nor mortality. In conclusion, reduced urinary NOx, reflecting lower NO 
production, is associated with adverse cardiovascular parameters as well as a higher 
risk of graft failure and all-cause mortality in RTR. 
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Introduction 
Kidney transplantation is the preferred treatment option for patients with end-stage renal 
disease (ESRD).1 Although kidney transplantation reduces mortality risk2 and improves 
quality of life for patients that were on dialysis before3, patient and graft survival remain 
a major problem. Particularly cardiovascular complications, such as hypertension and 
atherosclerosis, lead to graft loss or premature death.4,5 Moreover, the decline of graft 
function requires re-transplantation or return to dialysis sooner or later.6-8 
Nitric oxide (NO) is a pluripotent cell signalling and effector molecule involved 
in the control and regulation of an enormous variety of physiological processes. NO not 
only plays a critical role in cardiovascular homeostasis but also modulates fundamental 
processes spanning from cell proliferation over substrate utilisation to energy production 
across all major organ systems.9-10 In the kidney, NO plays an important role in renal 
and glomerular hemodynamics, promoting natriuresis and diuresis.11 Three isoforms of 
NO have been identified: inducible NOS (iNOS), neuronal NOS (nNOS) and endothelial 
NOS (eNOS).12 eNOS is the major enzyme in the vasculature that produces NO, and 
inhibition of its activity leads to both glomerular and systemic hypertension.13 In human 
renal tissue after kidney transplantation, we measured the urinary end-products of NO, 
nitrite (NO
2
-) and nitrate (NO
3
-), and examined the expression patterns of iNOS and 
eNOS.14,15 A role for NO in both acute and chronic transplant rejection was suggested, 
with lower levels of urinary nitrite and nitrate excretion during acute rejection and 
increased iNOS versus decreased glomerular eNOS expression levels in chronic renal 
transplant failure. This is in accordance with other pathophysiological conditions such 
as hypercholesterolemia, atherosclerosis and hypertension where impaired eNOS 
activity and endothelial dysfunction are observed.16-18 
While many of NO’s actions are mediated via the classical cyclic GMP/PKG 
pathway, a not insignificant part appears to be mediated in a cGMP-independent 
manner through the formation of nitroso species, a process by which an NO moiety 
is covalently incorporated into another biomolecule. This may occur by either 
post-translational modification of sulfhydryl or amino moieties in proteins or via 
formation of low-molecular weight nitrosothiols and nitrosamines. Potential roles 
of such nitrosative modifications have been described in the regulation of insulin 
signaling, mitochondrial energy metabolism, mRNA transcription, stress signaling, and 
endoplasmic reticulum function.19 A considerable amount of mechanistic detail has 
been unveiled in recent years about the regulatory role of these species at the cellular 
and sub-cellular level, but far less is known about their global regulation in vivo. While 
a circulating pool of nitrosated products has been demonstrated to exist in healthy 
humans20,21 we know little about the dynamics of their formation and excretion. To the 
best of our knowledge, the occurrence and possible role of urinary nitroso species in 




In the present study, we measured urinary nitrite and nitrate (measured 




- = NOx) as well as total nitroso species 
(RXNO) excretion, reflecting NO production and metabolism, in stable RTR and healthy 
controls. To quantify the former we used the commonly employed Griess reaction 
and compared the results to those obtained using the ‘gold standard’, HPLC. We 
subsequently investigated whether levels of urinary NOx and nitroso species were 
associated with cardiovascular parameters, all-cause mortality and graft failure. 
Methods
Study population
The study protocol was approved by the Institutional Review Board (METc RUG, 
Groningen, the Netherlands: 2008/186), in adherence to the Declaration of Helsinki. 
All stable RTR with a functional graft for at least one year who visited our outpatient 
department between 2008 and 2010 were invited to participate. All transplant 
procedures were performed in the University Medical Center Groningen, the 
Netherlands, and no RTR had any history of alcohol or drug addiction. In total, 707 RTR 
signed written informed consent (87% of invited). NOx was measured in 702 RTR (99%). 
For analyses regarding dietary intake, we excluded all patients with missing dietary 
data, resulting in 637 RTR. As a healthy reference group we included 107 subjects who 
were evaluated for living kidney donation in our center during the same period. 
Urine collection and rationale for the use of two distinct 
methods for quantification of nitrite/nitrate excretion 
All participants were instructed to collect urine over a 24h period. In advance of the 
urine collection, chlorhexidine was added to the urine container as an antiseptic 
agent in order to prevent bacterial growth and artificially increased amounts of 
nitrite due to nitrate reduction.22 Samples were aliquoted and kept frozen at -80° C 
until analysis. Measurement of combined urinary nitrite and nitrate (NOx) excretion 
is widely used as a marker of NO production.23,24 Despite the fact that the popular 
Griess assay is the most commonly used method for NOx determination worldwide, 
the specificity and accuracy of this method is not without problems.25,26 We sought 
to address these issues by comparing our results obtained by the Griess method 
with a highly sensitive and specific HPLC technique for simultaneous individual 
measurement of nitrite and nitrate. 
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Griess reaction for the determination of nitrite and nitrate
Urinary NOx excretion applying the classical Griess reaction was measured in 24-hour 
urine samples by sequential processing to determine nitrite and the sum of nitrite 
and nitrate. To determine nitrite, urinary samples (100 μl) were diluted fourfold 
with distilled water and deproteinized by addition of 20μl zinc sulphate (30%; 
Sigma Aldrich, St. Louis, MO, USA), followed by centrifugation at maximal speed 
(Eppendorf Centrifuge 5417R) for 5 min at RT. The supernatant (100 μl) was added in 
triplicate to the wells of a microtiter plate. Two wells were treated with 100 μl Griess 
reagent (Sulfanilamide (10 g/L; Sigma Aldrich), N-(1-naphthyl)-ethylenediamine 
dihydrochloride (1 g/L; Sigma Aldrich) and phosphoric acid (21.25 g/L; Sigma Aldrich) 
in distilled water). The third well was treated with 100 μl phosphoric acid (21.25g/L; 
Sigma Aldrich) only and served to obtain an individual background reading for 
each sample. After 5-10 minutes, the absorbance at 540 nm was measured using 
a microplate reader (EL808, Ultra microplate reader, Bio-Tek Instruments, Winooski, 
VT, USA). The mean of sample absorbance, measured in duplicate, was corrected for 
background reading and dilution factor and compared to the absorbance values of 
identically treated nitrite standards in distilled water (linear range between 0 and 100 
μmol/L) to calculate final sample concentrations.
To measure nitrate by the Griess reaction, prior enzymatic reduction to nitrite 
is needed. Thereafter, the sum of nitrite and nitrate is determined. By subtracting the 
concentrations of nitrite as determined before reduction from the sum of nitrite and 
nitrate following the reduction protocol, the concentrations of nitrate in the sample 
are obtained. Once daily, potassium nitrate (1mM) was included to check conversion 
efficiency of the enzymatic process. Urinary samples (100 μl) were diluted fourfold 
with distilled water. By adding 8 μl Aspergillus nitrate reductase (10 U/mL; Roche, Basel, 
Switzerland), 1μl of NADPH (100mM; Roche) and 1μl FAD (2mM; Sigma Aldrich) (all 
three-fold diluted in 20 mM Tris/HCl pH 7.4) to the sample, nitrate was enzymatically 
converted to nitrite during an incubation period of 30 min at 37° C in the dark. To 
oxidize remaining NADPH, which interferes with the assay, 40μl lactase dehydrogenase 
(100 mM; Roche) and 2μl sodium pyruvate (5 g/L; Sigma Aldrich) were added at the 
end of the reduction process, with further incubation for 5 min at 37° C. Sample 
deproteinization and absorbance measurement was as described for nitrite above. The 
calibration curves for nitrite and nitrate standards were linear between 1 and 100 µM, 




HPLC method for the determination of nitrite and nitrate 
The HPLC method used employs ion chromatography with on-line reduction of nitrate 
to nitrite and subsequent post-column derivatization with the Griess reagent using 
a dedicated analysis system (ENO-20, Eicom, Kyoto, Japan).27 Samples were subjected 
to deproteinization using ice-cold methanol (1:1 v/v) followed by centrifugation. A total 
volume of 10 µL of sample was loaded onto the column, resulting in a detection limit of 
10 nM for either anion. Results of both methods were compared using a Bland-Altman 
plot, which is a widely accepted statistical method to assess agreement between two 
different methods or assays.28 
Assessment of urinary nitroso species via gas phase 
chemiluminescence detection
Urinary RXNO concentrations were quantified in 24h urine samples using reductive 
denitrosation by triiodide (J
3
-) with subsequent detection of the liberated NO by gas-
phase chemiluminescence, as previously described.29 In short, samples were thawed 
for 30 min at RT. To prevent possible reaction of protein thiols with nitrite, samples were 
pretreated with N-ethylmaleimide (NEM; 10 mM final concentration) for the duration 
of 15 min at RT. Additionally, pre-incubation with of a 5% solution of sulphanilamide 
in 1 N HCl (final concentration of 29 mmol/L) was applied for another 15 min at RT, to 
efficiently remove nitrite. As a general measure, samples were kept in the dark to avoid 
photolytic decomposition of light-sensitive RXNOs. All samples were processed within 
a time frame of 15 – 30 minutes after start of the pre-incubation with sulphanilamide, 
and injected into a septum-sealed reaction chamber containing a 10 mM iodine/ 45 
mM iodide-containing reaction mixture in glacial acetic acid, continuously purged 
with high-purity nitrogen. The NO released from RXNOs into the gas phase was carried 
by the inert gar into the reaction chamber of the chemiluminescence detector where it 
reacts with ozone (O
3
) to form nitrogen dioxide (NO
2
). This chemiluminescent reaction 
emits light that is quantified by a photomultiplier. NO signal output was sampled at 5 
Hz and peak integration was performed using the ChromProcessor software (EDAQ 
PowerChrom Version 2.7.9). Aqueous nitrite standards processed in an identical manner 
were used to convert peak areas into absolute amounts of NO, allowing to determine 
sample concentrations by taking the injected sample volume into account. 
Assessment of dietary intake
Dietary intake was assessed using a validated semi-quantitative food frequency 
questionnaire (FFQ), which participants filled in themselves. More detailed information 
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about the procedure is available elsewhere.30 In short, for each of the 177 food items 
on the list, intake was recorded in times per day, week or month. Inconsistent answers 
were verified with the patients by a trained researcher, and FFQ validity in RTR was 
assessed by comparing excretion of several urinary components with intake of e.g. 
sodium, potassium and proteins. Dietary data was converted into daily nutrient intake 
using the Dutch Food Composition Table of 2006.31
Outcome measures
All measurements were performed during a morning visit to the outpatient clinic after 
an 8-12 h overnight fasting period. Blood pressure (mmHg) was measured according 
to a strict protocol as previously described.32 Participants were left alone in a room in 
half-sitting position while systolic blood pressure (SBP), diastolic blood pressure (DBP), 
mean arterial pressure (MAP) and heart rate were measured with a semi-automatic 
device (Dinamap® 1846, Critikon, Tampa, FL, USA). Measurements were performed 
every minute for fifteen minutes, and the average value of the last three measurements 
was used for analyses. Blood was drawn in the morning after completion of the 24h 
urine collection. Plasma and urinary concentrations of electrolytes, phosphate, albumin 
and urea were measured using routine clinical laboratory methods, as were serum 
cholesterol, HbA1c, hs-CRP and Nt-Pro-BNP-levels. Serum creatinine was determined 
using a modified version of the Jaffé method (MEGA AU 510, Merck Diagnostica, 
Darmstadt, Germany). Serum calcium was corrected for hypoalbuminemia (when 
<40 g/L; corrected calcium = serum calcium (mmol/L) + 0.02 x (40 – serum albumin 
[g/L]). Renal function was assessed by calculating the estimated glomerular filtration 
rate (eGFR) applying the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation.33 
Information on participants’ health status, medical history, and medication use 
was obtained from patient records. Information on smoking behaviour was obtained 
by using a questionnaire, with classification of participants as ‘current smokers’, ‘former 
smokers’, or ‘never smokers’. Body weight and height were measured, and Body Mass 
Index (BMI) was calculated as weight divided by height squared (kg/m2) while Body 
Surface Area (BSA) was estimated applying the universally adopted formula of DuBois 
& DuBois.34 
Statistical analyses
Data-analysis was performed using SPSS version 22.0 software (SPSS Inc., Chicago, IL, 
USA). Normality was tested with the Kolmogorov-Smirnov test, and skewed data were 




RXNO excretion and serum parathyroid hormone (PTH), alkaline phosphatase (AF), 
triglycerides, high sensitive C-reactive protein (hs-CRP) and N-terminal pro-hormone of 
brain natriuretic peptide (NT-pro-BNP), or by extracting the square root of original values 
(urinary NOx). Data in text and tables are presented as mean ± standard deviation (SD), 
unless stated otherwise. The study population was subdivided into gender-stratified 
tertiles to visualize potential associations of NOx excretion with different parameters 
in RTR. To establish p-values for differences in NOx tertiles an ANOVA was used for 
normally distributed continuous data, whereas the Kruskal-Wallis test was used for non-
normally distributed data and the χ2-test for nominal data. To identify the independent 
determinants of NOx excretion, univariable and multivariable linear regression analyses 
were performed. With backward selection (P
out
 > 0.05) multivariable linear regression 
models were constructed, which included all the variables that were significantly 
associated with NOx in the univariable analysis. The associations of several cardiovascular 
parameters with NOx excretion were investigated with multivariable linear regression 
analysis, with adjustment for age, gender and BSA (model 1) and subsequent addition 
of eGFR (model 2). In model 3, an additional adjustment was made for potential 
confounders of NOx excretion, identified with multivariable regression analyses (model 
3: smoking, serum triglycerides, use of calcineurin inhibitors or use of sirolimus). In the 
final model, we added uric acid excretion (model 4). Linear regression coefficients are 
given as standardized betas (st. β), to allow for comparison of the regression coefficients. 
Tertiles of NOx were tested for associations with all-cause mortality and death-censored 
graft failure by Kaplan-Meier analysis, including the log-rank test. 
For the Cox regression analysis, above described models were used, with 
addition of the crude model as a start. Mortality risk was presented as hazard ratio (HR) 
plus the 95% confidence interval. Within all statistical analyses, a two-sided P-value less 
than 0.05 was considered statistically significant.
Results
HPLC versus Griess assay for determination of NOx
In all 24h urine samples nitrate concentrations exceeded those of nitrite by several orders 
of magnitude. Figure 1 depicts the Bland-Altman plots of the results obtained with the 
HPLC method and the spectrophotometric Griess assay, for direct comparison of both 
techniques used to determine nitrate and nitrite concentrations. The y-axis represents 
the difference between the nitrate or nitrite values measured by HPLC and the value 
determined via the Griess assay, whereas the x-axis represents the average of both 
values. For nitrate, 35 out of 809 (4.3%) values did not meet the 95% limit agreement 
(Figure 1). Both methods showed comparable results for the nitrate values in the range 
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of 0 µM to 350 µM. However, nitrate values exceeding this limit were systematically 
underestimated by the classical Griess assay. In Figure 1 this is demonstrated by an 
upward linear deviation starting at nitrate values of 350 µM onwards. For nitrite, 18 out 
of 809 (2.2%) values did not meet the 95% limit of agreement (Figure 1). A dispersed 
pattern was seen, with a linear deviation in both positive and negative direction, when 
Figure 1. Bland-Altman plot of the HPLC vs. the Griess method for NOx detection
Comparison of nitrate and nitrite measured with HPLC and colorimetric Griess reaction. The Griess 
method underestimated nitrate values exceeding a mean value of 350 µmol, displayed by a positive 




HPLC measurements of nitrite were plotted against data obtained with the Griess assay. 
Of note, in 303 out of 809 (38%) samples the Griess method did not pick up any nitrite 
because absorbance values were below the detection limit of this method, while the 
HPLC technique always returned a value around or above the quantifiable limit. This 
distinction appears particularly important when nitrite concentrations need to be 
determined in urine samples as normal levels in this body fluid are typically below 1 µM.
Healthy control vs. RTR: baseline characteristics
Table 1 displays the characteristics of our study cohort. Both groups, healthy 
controls and RTR, were similar with regard to age, gender and BSA. Urinary nitrate 
excretion was significantly lower in RTR when compared to healthy participants (679 
[381 – 1047] µmol/24h vs. 1158 [850 – 1990] µmol/24h, p < 0.001). Since nitrate makes 
the greatest contribution to NOx levels, the same was true for NOx excretion (679 
[389 – 1053] µmol/24h vs. 1204 [879 – 2014] µmol/24h, p < 0.001). By contrast, mean 
urinary nitrite was significantly higher in RTR (0.20 [0.04 – 0.49] µmol/24h vs. 0.07 
[0.01 – 0.66] µmol/24h, p=0.03). Both systolic and diastolic blood pressure were higher 
in RTR (SBP: 136 ± 18 mmHg vs. 125 ± 15 mmgHg p < 0.001 and DBP 83 ± 11 mmHg 
vs. 75 ± 9 mmgHg p < 0.001). Unsurprisingly, RTR had a significant lower creatinine 
clearance (66 ± 26 mL/min vs. 132 ± 41 mL/min, p < 0.001) and eGFR (52 ± 20 mL/min 
vs. 93 ± 13 mL/min, p < 0.001), whereas serum creatinine levels and albumin excretion 
were significantly higher in RTR. Serum electrolytes were significantly different in 
RTR versus healthy controls with higher serum urea and lower serum albumin levels. 
Furthermore, serum triglycerides, glycated haemoglobin (HbA1c) and Nt-pro-BNP 
were all higher in RTR, as was hsCRP (all P < 0.001). Apart from differences in caloric 
intake (lower in RTR vs controls: 2175 ± 637 vs. 2309 ± 743 kCal, P = 0.02), dietary habits 
were similar between both groups. Vegetable consumption, which contributes to the 
majority of dietary nitrate intake, was not different between RTR and controls (93 ± 58 
vs. 92 ± 57 kCal, P = 0.9). 
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Table 1. Characteristics of healthy controls versus renal transplant recipients at 








NOx excretion (µmol/24h) 1204 [879 – 2014] 679 [389 – 1053] <0.001
Nitrite (µmol/24h) 0.07 (0.01 – 0.66] 0.20 [0.04 – 0.49] 0.03
Nitrate (µmol/24h) 1158 [850 – 1990] 679 [381–1047] <0.001
Demographics
Age (years) 53 ± 10 53 ± 13 0.77
Male gender, n (%) 53 (50) 401 (57) 0.16
BSA (m2) 1.97 ± 0.19 1.94 ± 0.22 0.26
Current smoker (%) 23 (22)  84 (13) <0.001
Hemodynamics
Systolic BP (mmHg) 125 ± 15 136 ± 18 <0.001
Diastolic BP (mmHg) 75 ± 9 83 ± 11 <0.001
MAP (mmHg) 92 ± 10 100 ± 12 <0.001
Heart Rate (bpm) 67 ± 10 69 ± 12 0.11
Renal function 
Serum creatinine (µmol/L) 73 [64 – 82] 125 [100 – 160] <0.001
Creatinine clearance (mL/min) 132 ± 41 66 ± 26 <0.001
eGFR (ml/min/1.73m²) 93 ± 13 52 ± 20 <0.001
Albumin (mg/24h) 5.5 [3.1 – 8.3] 41.6 [10.6 – 179] <0.001
Serum
Sodium (mmol/L) 143 ± 2 141 ±3 <0.001
Potassium (mmol/L) 3.84 ± 0.26 3.98 ± 0.47 <0.001
Chloride (mmol/L) 106 ± 2 105 ± 4 0.005
Urea (mmol/L) 5.7 [4.9 – 6.6] 9.6 [7.2 – 13.4] <0.001
Albumin (mmol/L) 45.2 ± 2.5 43.0 ± 3.0 <0.001
Cholesterol (mmol/L) 5.2 [4.5 – 5.9] 5.0 [4.3 – 5.8] 0.14
Triglycerides (mmol/L) 1.1 [0.8 – 1.6] 1.7 [1.3 – 2.3] <0.001
HbA1c (%) 5.55 ± 0.29 5.99 ± 0.83 <0.001
hsCRP (mg/L) 1.2 [0.5 – 2.3] 1.6 [0.7 – 4.6] 0.001
NT-pro-BNP (ng/L) 39 [20 – 65] 254 [109 – 614] <0.001
Data are presented as mean ± SD, % or median [interquartile range]. 
Abbreviations: NOx, combined urinary nitrite and nitrate; BSA, body surface area; BP, blood pressure; MAP, 
mean arterial pressure; eGFR, estimated Glomerular Filtration Rate; HbA1c, glycated hemoglobine; hsCRP, high-
sensitive C-Reactive Protein; MAP, mean arterial pressure; NT-pro-BNP, N-terminal pro-Brain Natriuretic Peptide. 




Patient characteristics: gender-stratified tertiles 
Urinary NOx excretion had a median value of 679 µmol/24h [389 – 1053] and was 
square root-transformed to meet normal distribution criteria (Figure 2). The patient 
cohort of 702 RTR had a mean age of 53.0 ± 12.7 years and 57% were male. Baseline 
characteristics of the patient cohort per gender-stratified tertiles are displayed in 
Table 2. Median time between renal transplantation and baseline measurement was 
5.4 [1.9 – 12.0] years. RTRs in the lowest tertile of urinary NOx were older and had 
higher systolic blood pressure, despite the fact that they used significantly more 
antihypertensives compared to RTR in the other tertiles. With regard to transplant 
characteristics, RTR with the lowest NOx excretion less often received their kidney from 
living donors, and their donors tended to be older. Renal function, hemoglobin, serum 
albumin and plasma bicarbonate were significantly lower in patients with reduced 
NOx excretion, whereas calcium, phosphate, PTH, total cholesterol and triglycerides 
were significantly higher. Moreover, RTR with the lowest urinary NOx had significantly 
higher levels of both hsCRP and NT-pro-BNP. With regard to urinary parameters, RTR 
with the lowest NOx excretion also had the lowest excretion of uric acid and thiosulfate 
and the highest excretion of albumin. Furthermore, use of vitamin K antagonists and 
calcineurin inhibitors was significantly higher in RTR with the highest NOx excretion. 
Figure 2. Histogram of NOx excretion
After square root-transformation, urinary excretion of NOx measured in 702 renal transplant 
recipients was normally distributed. 
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Table 2. Patients’ characteristics presented as gender-stratified tertiles of NOx 
excretion
Renal Transplant Recipients










NOx excretion (µmol/24 h) 679 [389-1053]  278 [158-386] 679 [571-777] 1362 [1053-1863] <0.001
Demographics
Age, yr 53.0±12.7 55.4±12.3 52.2±12.7 51.3±12.9 0.001
Current smoker, n (%) 83 (13) 18 (9) 29 (13) 36 (16) 0.05
Current diabetes, n (%) 170 (24) 61 (26) 59 (25) 50 (21) 0.44
BSA, m2 1.94±0.22 1.91±0.22 1.96±0.22 1.95±0.21 0.06
Systolic Blood Pressure, mmHg 136±18 138±18 137±18 133±16 0.01
Diastolic Blood Pressure, mmHg 83±11 82±11 84±11 82±11 0.23
Heart rate, bpm 68.6±12.0 68.6±12.5 69.1±11.9 68.0±11.4 0.52
Renal Transplantation
Transplant vintage, years 5.4 [1.9-12.0] 5.1 [1.7-12.2] 5.9 [2.2-12.2] 5.3 [2.0-11.0] 0.65
Living donor, n (%) 235 (34) 62 (27) 71 (31) 102 (44) <0.001
Pre-emptive KTx, n (%) 112 (16) 30 (13) 38 (16) 44 (19) 0.22
HLA mismatches, n 2 [1-3] 2 [1-3] 2 [1-3] 2 [1-3] 0.68
Age donor, years 42.9±15.5 44.5±15.7 40.9±15.4 43.2±15.2 0.04
Acute rejection, n (%) 188 (27) 66 (28) 68 (29) 54 (23) 0.28
Laboratory measurements
Haemoglobin, mmol/L 8.2±1.1 8.1±1.1 8.2±1.1 8.4±1.0 0.003
HbA1C, % 6.0±0.8 6.1±0.9 6.0±0.8 5.9±0.8 0.17
eGFR, CKD-EPI (ml/min/1.73m²) 52.2±20.2 46.0±20.0 53.7±20.2 56.9±18.8 <0.001
Corrected calcium mmol/L 2.34±0.15 2.36±0.16 2.34±0.15 2.33±0.13 0.04
Phosphate, mmol/L 0.96±0.21 0.98±0.23 0.98±0.21 0.93±0.20 0.01
Magnesium, mmol/L 0.95±0.12 0.95±0.13 0.95±0.12 0.96±0.12 0.92
PTH, pmol/L 8.9 [5.9-14.7] 11.21 [6.5-17.3] 8.8 [6.0-13.9] 8.1 [5.4-12.1] <0.001
Venous pH 7.37±0.04 7.37±0.04 7.37±0.04 7.37±0.04 0.12
Venous HCO₃¯, mmol/L 24.6±3.1 24.0±3.4 25.0±2.9 24.9±2.8 0.001
hsCRP, mg/L 1.6 [0.7-4.6] 1.9 [0.8-5.8] 1.6 [0.8-4.2] 1.3 [0.5-3.8] 0.002
Albumin, g/L 43.0±3.0 42.4±3.1 42.9±2.7 43.6±3.0 <0.001
Alkaline phosphatase, U/L 67 [53-83] 69 [55-89] 66 [52-80] 66 [54-82] 0.15
Total cholesterol, mmol/L 5.0 [4.3-5.8] 5.1 [4.4-6.0] 5.1 [4.4-5.8] 4.8 [4.3-5.5] 0.03
HDL cholesterol, mmol/L 1.3 [1.1-1.6] 1.3 [1.0-1.6] 1.3 [1.1-1.7] 1.3 [1.1-1.6] 0.18
LDL cholesterol, mmol/L 2.9 [2.3-3.5] 2.9 [2.4-3.5] 3.0 [2.3-3.6] 2.8 [2.3-3.3] 0.25
Triglycerides, mmol/L 1.68 [1.25-2.30] 1.85 [1.38-2.58] 1.69 [1.28-2.40] 1.52 [1.13-2.02] <0.001
NT-pro-BNP, ng/L 254 [109-625] 434 [177-1141] 261 [110-538] 147 [72-344] <0.001
Albuminuria, mg/24h 42 [11-178] 58 [14-212] 43 [12-211] 25 [8-110] 0.02
Uric acid, mmol/24h 2.58±0.98 2.20±0.86 2.63±0.93 2.95±1.00 <0.001
Thiosulfate, µmol/24h 7.02 [3.88-11.88] 5.73 [3.00-9.22] 6.42 [4.00-11.43] 9.38 [5.44-15.06] <0.001
Medication
Anti-hypertensives, n (%) 619 (88) 217 (93) 207 (88) 195 (83) 0.005
Statins, n (%) 370 (53) 133 (57) 125 (53) 112 (48) 0.20
Calcium supplements, n (%) 150 (21) 48 (21) 45 (19) 57 (24) 0.37
Vitamin D supplements, n (%) 173 (25) 56 (24) 55 (23) 62 (27) 0.72
Vitamin K antagonists, n (%) 78 (11) 35 (15) 26 (11) 17 (7) 0.03
Prednisone, mg/d 10 [7.5-10] 10 [7.5-10] 10 [7.5-10] 10 [7.5-10] 0.88
Calcineurin inihibitors, n (%) 403 (57) 150 (64) 134(57) 119 (51) 0.01
Proliferation inhibitor, n (%) 583 (83) 185 (79) 198 (84) 200 (86) 0.18
Sirolimus, n (%) 13 (2) 3 (1) 4 (2) 6 (3) 0.54
Data are presented as mean ± SD, percentage or median [IQR]. Statistical analysis was performed using ANOVA, Kruskal-Wallis or χ²-test 
when appropriate. Bold indicates statistical significance (P < 0.05). 
Abbrevations: BSA, body surface area; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HCO₃¯, bicarbonate; HDL, high-
density lipoprotein; HLA, human leukocyte antigen; hsCRP, high-sensitivity C-reactive protein; KTx, kidney transplantation; LDL, low-density 




Table 3. Associations of NOx with clinical parameters in RTR
NOx excretion
Univariable Multivariable
St. Beta P-value St. Beta P-value
Demographics
Age, years -0.082 0.03
Male gender 0.133 <0.001
Current smoker 0.110 0.005 0.151 <0.001
Current diabetes -0.069 0.07
BSA 0.167 <0.001 0.113 0.02
SBP, mmHg -0.086 0.02
DBP, mmHg -0.010 0.80
Heart rate, bpm -0.063 0.10
Renal Transplantation
Transplant vintage, years -0.007 0.85
Living donor 0.107 0.005
Pre-emptive KTx 0.017 0.65
HLA mismatches 0.025 0.52
Age donor, years -0.023 0.55
Acute rejection -0.030 0.43
Laboratory measurements
Hemoglobin, mmol/L 0.176 <0.001
HbA1C, % -0.062 0.11
eGFR, CKD-EPI (ml/min/1.73m²) 0.188 <0.001
Corrected calcium mmol/L -0.125 0.001
Phosphate, mmol/L -0.121 0.001
Magnesium, mmol/L 0.027 0.48
PTH, pmol/L -0.094 0.01
Venous pH 0.047 0.24
Venous HCO₃¯, mmol/L 0.096 0.01
hsCRP, mg/L -0.134 0.001
Albumin, g/L 0.164 <0.001
Alkaline phosphatase, U/L -0.004 0.92
Total cholesterol, mmol/L -0.106 0.005
HDL cholesterol, mmol/L 0.005 0.89
LDL cholesterol, mmol/L -0.049 0.20
Triglycerides, mmol/L -0.144 <0.001 -0.147 0.001
NT-pro-BNP, ng/L -0.302 <0.001
Albuminuria, mg/24h -0.052 0.17





Calcium supplements 0.040 0.29
Vitamin D supplements 0.050 0.19
Vitamin K antagonists -0.053 0.16
Prednisone, mg/d 0.034 0.37
Calcineurin inihibitors -0.120 0.001 -0.097 0.02
Proliferation inhibitor 0.031 0.41
Sirolimus 0.103 0.01 0.088 0.03
Regression coefficients are given as standardized betas, i.e. change of cardiovascular parameter in SD, per SD increase of urinary NOx excretion. 
Abbreviations: DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density 
lipoprotein; hsCRP, high-sensitive C-Reactive Protein; LDL, low-density lipoprotein; MAP, mean arterial pressure; NOx, combined nitrate and 
nitrate excretion; NT-pro-BNP, N-Terminal pro-hormone of Brain Natriuretic Peptide; SBP, systolic blood pressure.
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Table 3 provides an overview of associations of urinary NOx levels with different 
parameters in univariable and multivariable regression analyses. The strongest associations 
with NOx excretion in the multivariable analyses were smoking, BSA, serum triglycerides, 
urinary uric acid and the use of calcineurin inhibitors and sirolimus (model R2=27%). 
The regression coefficients for the association of urinary NOx with various 
cardiovascular parameters are given in Table 4. After adjustment for the strongest 
associates of NOx (model 4), urinary NOx excretion was inversely associated with 
systolic blood pressure (st. β = -0.094, P = 0.02), diastolic blood pressure (st. β = -0.083, 
P = 0.03), mean arterial pressure (st. β = -0.096, P = 0.01), serum hsCRP (st. β = -0.103, 
P = 0.01), serum Nt-pro-BNP (st. β = -0.200, P < 0.001) and HbA1c (st. β = -0.085, P = 0.04). 
Table 4. Regression coefficients for the association of urinary NOx with several 
cardiovascular parameters in RTR
NOx excretion
Model 1 Model 2 Model 3 Model 4
Cardiovascular risk factors St. β P St. β P St. β P St. β P
SBP, mmHg  -0.103 0.01 -0.085 0.02 -0.092 0.02 -0.094 0.02
DBP, mmHg -0.055 0.15 -0.044 0.24 -0.068 0.09 -0.083 0.03
MAP, mmHg  -0.082 0.03 -0.067 0.07 -0.086 0.03 -0.096 0.01
Heart rate, bpm  -0.051 0.19 -0.066 0.09 -0.010 0.81 -0.005 0.90
hsCRP, mg/L  -0.127 0.001 -0.115 0.002 -0.090 0.02 -0.103 0.01
NT-pro-BNP, ng/L  -0.297 <0.001 -0.253 <0.001 -0.243 <0.001 -0.200 <0.001
HbA1c, %  -0.074 0.06 -0.094 0.02 -0.072 0.08 -0.085 0.04
Albuminuria, g/24h  -0.080 0.04 -0.022 0.58 -0.016 0.70 -0.039 0.33
eGFR, mL/min  0.191 <0.001 - - 0.104 0.01 0.010 0.80
Model 1: corrected for age, gender and BSA
Model 2: corrected for model 1 plus eGFR 
Model 3: corrected for model 2 plus potential confounders (smoking, serum triglycerides, use of calcineurin 
inhibitors, use of sirolimus)
Model 4: corrected for model 3 plus uric acid excretion
Regression coefficients are given as standardized betas, i.e. change of cardiovascular parameter in SD, per SD 
increase of urinary NOx excretion. 
Abbreviations: DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitive 
C-Reactive Protein; HbA1c, glycated hemoglobin; MAP, mean arterial pressure; NOx, combined nitrite and 




Associations of NOx excretion with patient survival in RTR
Of the 702 RTR in our cohort, 83 (12%) died within a median follow-up period of 3.1 
[2.7 – 3.9] years. In the highest tertile of NOx excretion, 15 out of 234 (7%) died, while 
this was 24 out of 235 (10%) in the middle tertile and 44 out of 233 (19%) in the tertile 
with the lowest urinary NOx excretion (log-rank test P < 0.001, Figure 3). 
Additionally, we performed Cox regression analyses with potential confounders 
of urinary NOx excretion that were identified in the multivariable regression analyses 
(Table 5). The crude Cox regression analysis (model 1) showed that NOx excretion 
is inversely associated with mortality risk (HR 0.60 [95% CI 0.47 – 0.76], P < 0.001 per 
SD increase). After adjusting for age, gender and BSA (model 2; HR 0.62 [0.48 – 0.80], 
P < 0.001), for eGFR (model 3; HR 0.68 [0.52 – 0.88], P = 0.003) and potential confounders 
(model 4; HR 0.64 [0.48 – 0.87], P = 0.004), urinary NOx excretion remained significantly 
inversely associated with mortality risk in RTR. In the final model, urinary excretion of 
uric acid was added, which resulted in a borderline significant inverse association of 
NOx with mortality risk (model 5; HR 0.74 [0.54 – 1.02], P = 0.07).
Figure 3. Kaplan–Meier plot of the association of NOx excretion with all-cause mortality 
in RTR 
Higher excretion of NOx is associated with significant survival benefit in renal transplant recipients. 
Kaplan-Meier curve displayed for patient survival, with log-rank test P < 0.001. 
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Table 5. Associations of NOx excretion with all-cause mortality in RTR
NOx excretion (continuous)
HR (95% CI) per SD P-value
Model 1 0.70 [0.59 - 0.84] <0.001
Model 2 0.70 [0.58 – 0.85] <0.001
Model 3 0.75 [0.62 – 0.92] 0.005
Model 4 0.72 [0.57 – 0.90] 0.003
Model 5 0.78 [0.61 – 1.00] 0.05
Model 1: crude
Model 2: adjusted for age, gender and BSA
Model 3: adjusted for model 2 plus eGFR
Model 4: adjusted for model 3 plus smoking, serum triglycerides, use of calcineurin inhibitors, use of sirolimus
Model 5: adjusted for model 4 plus uric acid excretion 
Abbreviations: BSA, body surface area; CI, confidence interval; HR, hazard ratio; SD, standard deviation.
Median [IQR]: 679 [381 -1047] µmol/24 h
Associations of NOx excretion with graft failure in RTR
Graft failure was diagnosed in 45 out of 702 (7%) kidney recipients. In the highest 
tertile of NOx excretion, 6 out of 234 (3%) RTR developed graft failure. In the middle 
tertile graft failure occurred in 11 out of 235 (5%), while the RTR with the lowest NOx 
excretion had the highest risk of developing graft failure: 28 out of 233 (12%) (log-rank 
test P < 0.001, Figure 4). 
In Cox regression analyses (Table 6), the crude model (model 1) showed that NOx 
excretion is inversely associated with graft failure (HR 0.43 [95% CI 0.30 – 0.61], P < 0.001 
per SD increase). This inverse relationship remained significant after correction for 
age, gender and BSA (model 2; HR 0.41 [0.29 – 0.58], P < 0.001), eGFR (model 3; HR 0.59 
[0.41 – 0.86], P = 0.005), potential confounders (model 4; HR 0.54 [0.35 – 0.84], P = 0.01) 




Table 6. Associations of NOx excretion with graft failure in RTR
NOx excretion (continuous)
HR (95% CI) per SD P-value
Model 1 0.59 [0.48 - 0.73] <0.001
Model 2 0.58 [0.47 – 0.72] <0.001
Model 3 0.65 [0.50 – 0.85] 0.001
Model 4 0.64 [0.48 – 0.87] 0.003
Model 5 0.65 [0.48 – 0.88] 0.01
Model 1: crude
Model 2: adjusted for age, gender and BSA
Model 3: adjusted for model 2 and eGFR
Model 4: adjusted for model 3 plus smoking, serum triglycerides, use of calcineurin inhibitors, use of sirolimus
Model 5: adjusted for model 4 plus uric acid excretion 
Abbreviations: BSA, body surface area; CI, confidence interval; HR, hazard ratio; SD, standard deviation.
Median [IQR]: 679 [381 -1047] µmol/24 h
Association between NOx excretion and urinary nitroso species levels
Median excretion of total nitroso species (RXNO) was 0.28 [0.16 – 1.16] µmoles/24h 
in RTR, which was comparable to healthy controls (P = 0.23). Excretion of RXNO was 
significantly associated with nitrite excretion (R2=5.2%, st. β: 0.137, P = 0.001), whereas 
Figure 4. Kaplan–Meier plot of the association of NOx excretion with graft failure in RTR
Higher excretion of NOx is associated with significant better graft survival in renal transplant 
recipients. Kaplan-Meier curve displayed for graft survival, with log-rank test P < 0.001.
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there was no association with nitrate (P = 0.55). In multivariable regression analyses, 
urinary RXNO significantly associated with SBP (model 4; st. β -0.087, P = 0.04), MAP 
(model 4; st. β -0.082, P = 0.05) and albuminuria (model 4; st. β 0.095, P = 0.03). In survival 
analysis, nitroso species did neither predict for graft failure nor mortality. 
Discussion
Reduced urinary NOx excretion is associated with decreased patient survival and 
increased graft failure in stable kidney recipients. These associations remained significant 
after adjustment for potential confounders, with a borderline significance for the 
association with mortality upon addition of uric acid excretion. Furthermore, RTR with 
lower urinary NOx excretion had an adverse cardiovascular risk profile. A third important 
finding in this study is the markedly lower NOx excretion in RTR when compared to 
healthy controls, with no differences in the renal excretion of nitroso species.
The observational nature of our study does not allow to establish causality; 
however the strength of the associations would seem to justify further mechanistic 
studies. A reduced urinary NOx excretion in RTR may be the consequence of 
a decreased systemic production of NO, a disturbance in renal nitrate and nitrate 
handling, or a combination of both. NO is generated from L-arginine which is converted 
to L-citrulline by nitric oxide synthase (NOS). In healthy subjects, the majority of the 
circulating L-arginine pool is synthesized by the kidney and reabsorbed in the proximal 
tubuli.35-37 In RTR, renal dysfunction may be the cause of a decreased production 
and failed tubular reabsorption of L-arginine.38 L-arginine formation is known to be 
decreased in patients with chronic kidney disease (CKD).39 Furthermore, an increased 
expression and activity of arginase and thus use of L-arginine for the production of 
ornithine and urea (instead of citrulline and NO) may also compromise NO production40; 
to this end, a recent animal experimental study has unmasked a reciprocal relationship 
between circulating nitrate levels and arginase expression/L-arginine availability.41 The 
difference in NOx excretion between RTR and healthy controls in our study cannot be 
explained, however, by differences in dietary intake, which was comparable in both 
groups. Inhibitors of endogenous NOS, like asymmetric dimethylarginine (ADMA), can 
also play a role in decreased NO production in RTR, since it has been demonstrated 
that plasma ADMA levels are increased in patients with CKD42-44 as well as in patients 
after renal transplantation.45 Thus, endothelial and renal dysfunction in RTR may lead to 
decreased NO availability and as a consequence higher susceptibility to cardiovascular 
disease, graft failure and all-cause mortality. This notion is in line with our findings that 
decreased urinary excretion of NOx in RTR is associated with higher systolic, diastolic 
and mean arterial blood pressure, higher levels of hsCRP, HbA1c and Nt-pro-BNP and 




Inadequate NO production in the kidneys plays a key role in the development and 
progression of kidney disease. Experimentally induced chronic NOS inhibition causes 
systemic and glomerular hypertension, proteinuria and renal damage.24,46 Furthermore, 
in experimental models of renal mass reduction47, chronic glomerulonephritis48 and 
aging49, decreased total NOx excretion has been reported. NO deficiency also develops 
as a consequence of CKD24,50, with a decreased NOx excretion in these patients.51 
Patients with moderate and severe renal failure had significantly lower urinary NOx 
excretion when compared to mild renal failure and healthy controls52, and the same 
holds true for patients with end stage renal disease that are on dialysis.53 Decreased 
total NO production in CKD patients likely reflects systemic endothelial dysfunction, 
rather than a decreased NO production in the kidneys alone as the latter makes only 
a minor contribution to whole body NO production.46 
Nitrate represents the major stable endproduct of NO metabolism.54,55 While 
there is unanimous agreement about the significance of the kidney in nitrate excretion 
surprisingly little quantitative information is available about the role of this organ in 
controlling circulating NOx concentrations and the extent of renal reabsorption and 
tubular secretion. Nitrite and nitrate are widely believed to be handled in a very similar 
fashion by the kidney, although there is little evidence in support of this assumption 
in the literature. A recent pharmacological inhibitor study in a handful of healthy 
volunteers indicated the possible involvement of carbonic anhydrase in renal nitrite 
reabsorption56 but no other studies appear to have been performed to identify 
a specific renal nitrate transporter. Despite this paucity of information about specific 
proteins involved in renal NOx reabsorption, it has become increasingly clear in the last 
couple of years that nitrate can be reduced to nitrite and further to NO in an oxygen-
dependent fashion. This realization has led to the conceptualization of the existence 
of an alternative pathway of NO production that takes advantage of this sequential 
reduction57, which is inhibited by oxygen.58 Xanthine oxidoreductase appears to be 
involved in tissue nitrate reduction59, its expression is increased in the transplanted 
kidney (unpublished data), and an increased nitrate consumption via this reductive 
pathway may conceivably lead to lower apparent nitrate excretion. Thus, while our 
finding of reduced NOx excretion in RTR is consistent with the notion that systemic NO 
production is impaired we cannot exclude the possibility that this observation may be 
caused by alterations in renal handling instead. 
In the present study we compared the classical Griess assay with the current gold 
standard for nitrite and nitrate determination, high pressure liquid ion chromatography 
(HPLC). While the technical limitations of the former for quantitative analyses in 
complex biological matrices such as blood and urine are well recognised25,26 this 
methodology continues to enjoy great popularity because of its (apparent) simplicity, 
moderate costs and the possibility to process large numbers of samples in an efficient 
manner. However, the Griess method has its limitations when it comes to sensitivity 
and accuracy: concentrations below 1-2 µM are prone to large errors, and sensitivity is 
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limited to about 0.5 µM. Urine is a particularly problematic body fluid because nitrite 
concentrations are typically below 1 µM and nitrate concentrations are extremely 
high (potentially requiring a series of dilutions of unknown samples to ensure linearity 
of response, which becomes a serious limitation when processing large numbers of 
samples). By directly comparing high pressure liquid ion chromatography with the 
spectrophotometric Griess assay we here demonstrate that the Griess method tends to 
underestimate high nitrate values, possibly as a result of too short an exposure time or 
cofactor limitation for the enzymatic reduction (or a combination of both). Moreover, 
in a considerable number of samples nitrite values were below the detection limit of 
the Griess assay. The good news in the context of the main findings of our study is that 
a reduction in urinary nitrate excretion can easily be picked up with an assay that does 
not distinguish between nitrite and nitrate but only measures the sum of both, NOx.
We have to acknowledge that the present study has some limitations. Causality 
is hard to prove since the study has a cross-sectional design. Furthermore, the single-
centre set-up and the fact that most of the RTR were of Caucasian origin might limit 
generalizability. However, the large population size, the use of 24h urine samples to 
determine NOx excretion, the comparison of two different methods to measure nitrite 
and nitrate, the assessment of dietary intake and extensive data collection that allowed 
adjustment for potential confounders and the comparison between RTR and healthy 
subjects, all contribute to the reliability and robustness of our findings. 
In conclusion, reduced NOx excretion in RTR is associated with an adverse 
cardiovascular risk profile, increased graft failure and higher all-cause mortality 
in RTR. Further studies have to be conducted to determine whether this is rather 
a consequence of endothelial dysfunction, a changed renal handling or a combination 
of both. 
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